ALNY
Alnylam Pharmaceuticals, Inc.
ALNY's fundamentals are strong: revenue grew 56% and its operating margin rose 11 points to 20%. At 8.0x earnings, it's trading less than half its usual 76x. Analysts expect that strong growth to continue, though they disagree widely on how much.
ALNY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
ALNY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ALNY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 8x | $157 | — |
| Forward | 22x | $157 | — |
| Cheap | 41x | $800 | +411% |
| Fair | 76x | $1,489 | +851% |
| Expensive | 1,731x | $33,895 | +21538% |
Historical ranges are pointers, not guarantees.
ALNY's PE is in its cheap range at 8.0x. On analysts' estimates for next year's earnings, today's price would be 22x.
ALNY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for ALNY, but weaker profitability. However, they disagree widely on these estimates.
ALNY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $7.04 | -64% |
| Q3 2026 | $19.58 | +8413% |
| Q2 2026 | $5.70 | +$8.18 |
| Q1 2026 | $3.98 | +$6.08 |
| Q4 2025 | $2.03 | +$4.21 |
| Q3 2025 | $0.23 | +$2.81 |
| Q2 2025 | -$2.48 | -$1.92 |
| Q1 2025 | -$2.10 | +$0.54 |
| Q4 2024 | -$2.18 | +$1.34 |
ALNY's earnings per share have jumped to their highest in seven years: $19.58 over the past year, up from $0.23 the year before.
ALNY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.5B | +17% |
| Q2 2026 | $1.3B | +67% |
| Q1 2026 | $1.2B | +96% |
| Q4 2025 | $1.1B | +85% |
| Q3 2025 | $1.2B | +149% |
| Q2 2025 | $773.7M | +17% |
| Q1 2025 | $594.2M | +20% |
| Q4 2024 | $593.2M | +35% |
ALNY's revenue has grown year over year for eight quarters in a row: $1.5B last quarter, up 17% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 24% | -5.7 points |
| Q2 2026 | 18% | +20 points |
| Q1 2026 | 23% | +20 points |
| Q4 2025 | 12% | +30 points |
| Q3 2025 | 29% | +45 points |
| Q2 2025 | -2.1% | -9.5 points |
| Q1 2025 | 3% | +12 points |
| Q4 2024 | -18% | +8.7 points |
ALNY's operating margin was 24% last quarter, down 5.7 points from the same quarter a year ago.
ALNY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $271.2M | -13% |
| Q2 2026 | $292M | +109% |
| Q1 2026 | $48.7M | +$176M |
| Q4 2025 | $140.3M | +$244M |
| Q3 2025 | $313M | +692% |
| Q2 2025 | $139.4M | +20% |
| Q1 2025 | -$127.3M | -$32.8M |
| Q4 2024 | -$103.8M | -$58.7M |
ALNY has burned cash in most quarters: $752M over the past year, about three times what it generated the year before.
ALNY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -241K shares |
| 1 year | +0.5% | +692K shares |
| 3 years | +5.1% | +6.7M shares |
| 5 years | +16% | +18.9M shares |
| Available history | +24% | +26.3M shares |
ALNY has 138M diluted shares, up 0.5% from a year ago.
ALNY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.7x | Net Cash |
| Q2 2026 | -1.6x | Net Cash |
| Q1 2026 | -2.1x | Net Cash |
| Q4 2025 | -3.0x | Net Cash |
| Q3 2025 | -4.6x | Net Cash |
| Q2 2024 | -6.1x | Net Cash |
ALNY has more cash than debt.
ALNY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 28.6 | Oversold |
| Stochastic | 2.9 | Oversold |
ALNY's weekly RSI is 29 (oversold) and its Stochastic is 3 (oversold).
ALNY PE vs Healthcare Sector
| Metric | ALNY | Sector median | Relative |
|---|---|---|---|
| PE | 8x | 26x | 69% below |
| PE % | 2 | 29 | 27 pts below |
ALNY is trading at 8.0x earnings, a 69% discount to the Healthcare sector's median of 26x.
ALNY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $205.2 | 24% below |
| 20 week MA | $233.7 | 33% below |
| 50 week MA | $293.0 | 47% below |
| 100 week MA | $314.6 | 50% below |
| 200 week MA | $257.7 | 39% below |
ALNY is in a downtrend: it's below all five of its weekly moving averages, and 39% below its 200-week average.
ALNY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $117.5 | $137.6 | +17% |
| 2021 | $137.6 | $194.4 | +41% |
| 2022 | $194.4 | $237.9 | +22% |
| 2023 | $237.9 | $191.4 | -20% |
| 2024 | $191.4 | $238.0 | +24% |
| 2025 | $238.0 | $400.6 | +68% |
| 2026 YTD | $400.6 | $156.7 | -61% |
ALNY is down 61% so far in 2026, after finishing higher in five of the previous six years.